Loading clinical trials...

Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH) | Clinical Trials | Clareo Health

RECRUITINGPHASE2

Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)

Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (DISH)

NCT04566991•Aditya S. Pandey, MD

Summary

Aneurysmal subarachnoid hemorrhage (aSAH) has a high incidence of mortality and significant morbidity, with mortality exceeding 30% in the first two days.The initial injury is related to increasing intracranial pressure, cerebral edema, and neuronal injuries associated with the release of iron. Iron has been shown to increase the incidence of cerebral edema, ischemia, and formation of hydrocephalus. Deferoxamine mesylate (DFO), a hydrophilic chelator, creates a stable complex with free iron thus preventing the formation of iron related free radicals. This trial will evaluate the safety and efficacy of clinical deferoxamine for the treatment of aSAH for patients that are admitted to the hospital at the University of Michigan. Eligible participants will be enrolled and randomized to 1 of 2 doses of Deferoxamine or placebo (saline). Information regarding the patients will be collected and followed for up to 6 months post discharge.

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Aneurysmal SAH confirmed with vascular imaging
•Aneurysm treated with endovascular or microsurgical intervention
•Hunt-Hess ≤ 4
•Modified Fisher Grade I-IV
•Glasgow Coma Scale (GCS) ≥ 7 following External Ventricular Drain (EVD) placement if indicated
•First dose of drug can be administered within 24 hours of symptom onset
•Functional independence prior to SAH, Modified Rankin Scale (mRS) ≤ 1
•Informed consent obtained by patient or legal authorized representative (LAR)

Exclusion Criteria

•Previous hypersensitivity to or treatment with deferoxamine
•Presence of giant aneurysm (\>25 mm in size)
•Known severe iron deficiency anemia, Hemoglobin (Hgb) g/dl ≤ 7 or transfusion dependent
•Irreversibly impaired brainstem function
•Abnormal renal function, Serum Creatinine\> 2 mg/dL
•Pre-existing severe disability, mRS ≥ 2
•Coagulopathy, including use of anti-platelet or anticoagulant drugs
•Known severe hearing loss
•Chronic pulmonary disease that limits basic activities of daily living at baseline, or requires the use of home oxygen.
•Acute pulmonary disease with the need for any of the following - in a 72 hour period prior to enrollment: \>4L/minute nasal cannula (or equivalent O2 delivery via face mask/ tent), heated-high flow nasal cannula, noninvasive positive pressure ventilation, and in intubated patients FiO2\>45% or positive end-expiratory pressure (PEEP) \> 8cmH2O. This does not include the use of supplemental oxygen in any form for pre-oxygenation, apneic oxygenation, or peri-procedural support alone.
+8 more criteria

Locations (1)

University of Michigan

Ann Arbor, Michigan, United States

Key Dates

Start Date

March 20, 2022

Primary Completion Date

October 1, 2027

Completion Date

October 1, 2027

Last Updated

November 28, 2025

Enrollment

120

ESTIMATED participants

Conditions

Aneurysmal Subarachnoid Hemorrhage

Interventions

Deferoxamine

DRUG

Placebo

DRUG

Contacts

Sravanthi Koduri

CONTACT

734-647-7960 skoduri@med.umich.edu

Aditya Pandey, MD

CONTACT

734-615-2763 adityap@umich.edu

DIND in Patients With aSAH : Real World Study

NCT07160088

Aneurysmal Subarachnoid Hemorrhage (aSAH)

View study

RECRUITINGPHASE2

FLudrocortisone Administration in Aneurysmal Subarachnoid Haemorrhage

NCT06409364

Aneurysmal Subarachnoid Hemorrhage

View study

RECRUITINGPHASE2

Improving Outcome in Subarachnoid Hemorrhage wIth Nadroparine

NCT04507178

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 28, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)

Inclusion Criteria

Exclusion Criteria

DIND in Patients With aSAH : Real World Study

FLudrocortisone Administration in Aneurysmal Subarachnoid Haemorrhage

Improving Outcome in Subarachnoid Hemorrhage wIth Nadroparine

Prevention of Vasospasm in SAH Through CSF Treatment

Long-term Prognosis of Emergency Aneurysmal Subarachnoid Hemorrhage

Dome-Only Aneurysm Coiling in Severe Aneurysmal Subarachnoid Hemorrhage